Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2016-10-07 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on Mustang Bio, Inc.'s Amendment No. 1 to Registration Statement on Form 10-12G. It discusses revisions to disclosures in the registration statement, including business, financial information, and directors' biographies. The document is a correspondence related to a regulatory filing (Form 10-12G) and does not contain financial statements or substantive financial data itself. It is not the registration statement itself but a response letter to SEC comments. The document length is 4501 characters, which is relatively short and consistent with a regulatory correspondence. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such SEC comment response letters and related regulatory communications that do not fit other categories.
2016-10-07 English
10-12G/A
Annual Report Classification · 95% confidence The document is a SEC filing titled 'FORM 10/A (Amendment No. 2)' for Mustang Bio, Inc. It is a registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. The content includes detailed business description, risk factors, financial information, properties, management, executive compensation, legal proceedings, and financial statements. The document is comprehensive and contains substantive financial and business information typical of a full annual or periodic report. The presence of a table of contents with items such as Business, Risk Factors, Financial Information, and Financial Statements indicates this is a full report rather than an announcement or a certification. The form 10 is a type of annual report filed by companies not subject to 10-K requirements but still providing comprehensive information. Given the detailed nature and length (15,000 characters), this is best classified as an Annual Report (10-K equivalent).
2016-10-07 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a material definitive agreement related to a private placement of equity securities, including details of the transaction, placement agent fees, and warrants issued. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a financing transaction. The document length is about 5,343 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-10-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, reporting a change in the company's independent registered public accounting firm. It details the dismissal of the previous auditor, Mayer Hoffman McCann P.C., and the appointment of a new auditor, BDO USA, LLP. The content focuses on auditor changes and includes a letter from the former auditor. There are no financial statements or detailed audit reports included, only the announcement of the change. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and filings that do not fit other specific categories. The document length is 4575 characters, which is relatively short and consistent with an announcement rather than a full audit report.
2016-10-05 English
Regulatory Filings 2016
Regulatory Filings
2016-09-23 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on Mustang Bio, Inc.'s Form 10-12G registration statement filed on July 28, 2016. It discusses amendments to the Form 10-12G, responses to SEC comments on business description, risk factors, licensing agreements, and other disclosures. The document is not a financial report itself but a correspondence related to a regulatory filing. It references the Form 10-12G and amendments but does not contain financial statements or substantive financial data. The document is a regulatory correspondence responding to SEC comments, which fits the category of Regulatory Filings (RNS).
2016-09-15 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.